1332895-44-9Relevant academic research and scientific papers
Prodrugs of reverse fosmidomycin analogues
Brücher, Karin,Gr?wert, Tobias,Konzuch, Sarah,Held, Jana,Lienau, Claudia,Behrendt, Christoph,Illarionov, Boris,Maes, Louis,Bacher, Adelbert,Wittlin, Sergio,Mordmüller, Benjamin,Fischer, Markus,Kurz, Thomas
, p. 2025 - 2035 (2015)
Fosmidomycin inhibits IspC (Dxr, 1-deoxy-d-xylulose 5-phosphate reductoisomerase), a key enzyme in nonmevalonate isoprenoid biosynthesis that is essential in Plasmodium falciparum. The drug has been used successfully to treat malaria patients in clinical
Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr)
Behrendt, Christoph T.,Kunfermann, Andrea,Illarionova, Victoria,Matheeussen, An,Pein, Miriam K.,Gr?wert, Tobias,Kaiser, Johannes,Bacher, Adelbert,Eisenreich, Wolfgang,Illarionov, Boris,Fischer, Markus,Maes, Louis,Groll, Michael,Kurz, Thomas
, p. 6796 - 6802 (2011/12/04)
Reverse hydroxamate-based inhibitors of IspC, a key enzyme of the non-mevalonate pathway of isoprenoid biosynthesis and a validated antimalarial target, were synthesized and biologically evaluated. The binding mode of one derivative in complex with EcIspC
